Patents Assigned to TOKYO UNIVERSITY OF SCIENCE FOUNDATION
-
Publication number: 20250146897Abstract: A rubber product capable of easily and accurately detecting the presence or absence of leakage and a position of the leakage is provided. A rubber product includes a gas chromic material that changes a color thereof reversibly or changes an electric resistance value thereof, due to oxidation-reduction reaction. The rubber product is a sealing member (sealing product 10) for sealing a gap between two members, wherein the sealing member includes a gas chromic material that changes a color thereof reversibly or changes an electric resistance value thereof, due to oxidation-reduction reaction, and has a ring shape.Type: ApplicationFiled: October 7, 2022Publication date: May 8, 2025Applicants: NOK CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Takayuki SAKURAI, Kentaro OSADA, Hikaru TADANO, Tomohiro KAWAI, Keishi NISHIO
-
Patent number: 12286348Abstract: An embodiment of the present invention provides a noble gas hydride having the following formula 1: NgnHm. In formula 1, Ng represents a noble gas atom, n represents an integer from 1-8, and m represents an integer from 1-46.Type: GrantFiled: July 6, 2020Date of Patent: April 29, 2025Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventor: Kazuo Watanabe
-
Patent number: 12191088Abstract: A power generator includes a power generating unit and at least one of a power storage unit or an output unit that is electrically connected to the power generating unit. The power generating unit includes an electret having a first charged surface and a second charged surface that are charged with opposite polarities, a first electrode formed on the first charged surface, and a second electrode formed on the second charged surface. The electret is formed by polarizing an electret material that includes an inorganic dielectric having a bandgap energy of 4 eV or more. At least one of the first electrode or the second electrode are partially disposed on the corresponding charged surface such that at least one of the first charged surface or the second charged surface has a portion as a current collecting surface exposed outward.Type: GrantFiled: August 12, 2022Date of Patent: January 7, 2025Assignees: DENSO CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Yoshihiro Kozawa, Noriyuki Matsushita, Kazuhiko Kano, Yumi Tanaka, Hiroki Otsuka, Yusuke Edano
-
Patent number: 12119184Abstract: A power generator includes an electret including a first charged surface and a second charged surface having opposite polarities, a first electrode partially formed on the first charged surface, a second electrode formed on the second charged surface, a third electrode disposed to face the first charged surface with a space, and at least one of a power storage unit or an output unit. The first charged surface has a current collecting surface that is exposed outward. The first electrode and the second electrode form a first power generating unit and the third electrode and the second electrode form a second power generating unit. The electret is formed by polarizing an electret material that includes an inorganic dielectric having a bandgap energy of 4 eV or more.Type: GrantFiled: August 12, 2022Date of Patent: October 15, 2024Assignees: DENSO CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Yoshihiro Kozawa, Noriyuki Matsushita, Kazuhiko Kano, Yumi Tanaka, Hiroki Otsuka, Yusuke Edano
-
Patent number: 11996596Abstract: A power generation device, comprising a fuel, an anode and a cathode, the anode comprising an enzyme that promotes oxidation of the fuel, and the power generation device containing more water when generating power than when not generating power.Type: GrantFiled: September 28, 2017Date of Patent: May 28, 2024Assignees: TOKYO UNIVERSITY OF SCIENCE FOUNDATION, UNIVERSITY OF TSUKUBAInventors: Isao Shitanda, Seiya Tsujimura
-
Publication number: 20240156796Abstract: The present invention provides a pharmaceutical composition for the treatment or prevention of stress-related disorders, stress-induced anxiety disorders, or stress-related disorders or anxiety disorders associated with depression, the composition containing a selective ?-opioid receptor agonist as an active component, wherein the selective ?-opioid receptor agonist preferably also has a ?-opioid receptor antagonist action and a ?-opioid receptor antagonist action.Type: ApplicationFiled: February 25, 2022Publication date: May 16, 2024Applicants: TOKYO UNIVERSITY OF SCIENCE FOUNDATION, NIPPON CHEMIPHAR CO., LTD.Inventors: Akiyoshi SAITOH, Daisuke YAMADA, Eriko NAKATA
-
Publication number: 20240127982Abstract: An information processing apparatus includes a converting portion having a plurality of electrical conductors to be arranged in mutual separation and a medium arranged so as to mutually connect the plurality of electrical conductors, wherein the converting portion is the information processing apparatus to convert an input signal to an output signal. The medium includes the electrolyte and is configured to be capable of controlling an electrical conductivity of an electrically conductive path mutually electrically connecting the plurality of electrical conductors, and the medium is selected such that the electrical conductivity of the electrically conductive path changes over time with the input signal not being present.Type: ApplicationFiled: January 27, 2022Publication date: April 18, 2024Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, TOKYO UNIVERSITY OF SCIENCE FOUNDATION, TOYOTA PHYSICAL AND CHEMICAL RESEARCH INSTITUTE, NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, NAGASE & CO., LTD.Inventors: Hiroyuki AKINAGA, Hisashi SHIMA, Yasuhisa NAITOH, Hiroshi SATOU, Dan SATOU, Takuma MATSUO, Kentaro KINOSHITA, Toshiyuki ITOH, Toshiki NOKAMI, Masakazu KOBAYASHI
-
Patent number: 11932666Abstract: Provided is a polymerizable compound represented by a Formula E-1 or Formula E-2 shown in the description. In Formula E-1 or Formula E-2, R1 represents an alkoxy group, —NRN2, a hydroxy group, an aryl group, or an alkyl group, wherein RN each independently represents a hydrogen atom or an alkyl group having 1 to 10 carbon atoms; n represents an integer from 1 to 5; R3 represents a hydrogen atom, an acetyl group, a phenoxyacetyl group, a pivaloyl group, a benzyl group, a 4-methoxybenzyl group, a benzoyl group, a triphenylmethyl group, a 4,4?-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, a trimethylsilyl group, a cyanomethoxymethyl group, a 2-(cyanoethoxy)ethyl group, or a cyanoethoxymethyl group; and X represents a structure represented by any one of Formula B-1 to Formula B-5 shown in the description.Type: GrantFiled: October 13, 2022Date of Patent: March 19, 2024Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Takeshi Wada, Tatsuya Saito, Yuka Ishii, Yohei Nukaga
-
Patent number: 11920076Abstract: A fire retardant material comprising a carbon fiber which tensile elasticity is 700 GPa or more, and a fire retardant resin such as polycarbonate.Type: GrantFiled: October 12, 2018Date of Patent: March 5, 2024Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Koichi Yonemoto, Kiyoto Murakami, Satoshi Nonaka
-
Patent number: 11919932Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: GrantFiled: January 3, 2023Date of Patent: March 5, 2024Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
-
Patent number: 11917919Abstract: An electret includes a substrate and an electret layer formed above a surface of the substrate. The electret layer is a composite metal compound containing two or more different metal elements, and is obtained by subjecting a thin film mainly composed of an inorganic dielectric material having a bandgap energy of 4 eV or more to a polarization treatment.Type: GrantFiled: December 9, 2020Date of Patent: February 27, 2024Assignees: DENSO CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Noriyuki Matsushita, Yoshihiro Kozawa, Kazuhiko Kanoh, Yumi Tanaka
-
Patent number: 11915883Abstract: An electret includes an electret layer. The electret layer is formed by subjecting a composite film in which inorganic dielectric particles are dispersed and held in a base film to a polarization treatment. The inorganic dielectric particles are mainly composed of an inorganic dielectric material having a bandgap energy of 4 eV or more.Type: GrantFiled: December 9, 2020Date of Patent: February 27, 2024Assignees: DENSO CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Noriyuki Matsushita, Yoshihiro Kozawa, Kazuhiko Kanoh, Yumi Tanaka, Hirotoshi Otsuka, Yuki Kotaka
-
Publication number: 20240019430Abstract: Novel factors which are involved in the mechanism of the onset of IgA nephropathy are explored, and diagnostic, preventive or therapeutic agents for this disease are provided. A method for measuring autoantibodies related to IgA nephropathy, the method comprising measuring the amount of anti-spectrin ? IgA antibodies in a sample derived from a living organism.Type: ApplicationFiled: December 3, 2021Publication date: January 18, 2024Applicants: JUNTENDO EDUCATIONAL FOUNDATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Yusuke SUZUKI, Yoshihito NIHEI, Daisuke KITAMURA
-
Patent number: 11817261Abstract: An ink includes a boron-doped nanodiamond having a specific surface area of 110 m2/g or greater, and electrical conductivity at 20° C. of 5.0×10?3 S/cm or greater.Type: GrantFiled: November 18, 2021Date of Patent: November 14, 2023Assignees: DAICEL CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Takeshi Kondo, Tatsuo Aikawa, Makoto Yuasa, Kenjo Miyashita, Masahiro Nishikawa, Takahiro Tei
-
Patent number: 11742153Abstract: Provided is an electrode-forming material for an electrochemical capacitor useful for forming an electrode of an electrochemical capacitor having a high storage capacity and a high energy density. The electrode-forming material for an electrochemical capacitor according to an embodiment of the present invention includes boron-doped nanodiamond (A) having a specific surface area of 110 m2/g or greater and an electrical conductivity at 20° C. of 5.0×10?3 S/cm or greater; and a metal oxide (B), and the content of the (B) is from 20 to 95 mass % with respect to the total content of the (A) and (B).Type: GrantFiled: February 28, 2020Date of Patent: August 29, 2023Assignees: DAICEL CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Takeshi Kondo, Toshifumi Tojo, Makoto Yuasa, Kenjo Miyashita, Atori Miki, Masahiro Nishikawa, Takahiro Tei
-
Patent number: 11718590Abstract: A compound represented by Chemical formula 1: wherein n is an integer of 2 or more, is provided. Also provided is a derivatization reagent for derivatizing a diene-containing compound, including a compound represented by Chemical formula 1. Further provided is a synthesis method for a compound, including a nucleophilic substitution reaction between an aryl halide and a heterocyclic amine compound being saturated, the compound being represented by Chemical formula 1.Type: GrantFiled: December 21, 2021Date of Patent: August 8, 2023Assignees: TOKYO UNIVERSITY OF SCIENCE FOUNDATION, JEOL Ltd.Inventors: Tatsuya Higashi, Shoujiro Ogawa, Masaki Takiwaki, Seketsu Fukuzawa
-
Publication number: 20230220022Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: January 3, 2023Publication date: July 13, 2023Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
-
Patent number: 11578132Abstract: It is an object of the present invention to provide a method for efficiently producing a B cell population comprising B cells that recognize a specific antigen. According to the present invention, provided is a method for producing a B cell population, comprising: a step (c) of culturing a cell population comprising B cells together with a specific antigen in the absence of IL-21, in the absence of IL-4, and in the presence of a cytokine other than IL-21 and IL-4, while giving stimulation mediated by CD40 and a BAFF receptor to the cells; and a step (d) of culturing the cell population comprising B cells, while giving stimulation mediated by has to the cells, so as to obtain a B cell population comprising B cells that recognize the specific antigen.Type: GrantFiled: January 15, 2018Date of Patent: February 14, 2023Assignees: KANEKA CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Tatsuya Moutai, Tomoyuki Nakaishi, Hiroshi Kita, Mitsuaki Kitano, Daisuke Kitamura
-
Patent number: 11572393Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: GrantFiled: March 7, 2019Date of Patent: February 7, 2023Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
-
Patent number: 11558694Abstract: An electret includes a composite oxide having an ABO3 type perovskite structure containing two different metal elements A and B. The composite oxide is in a polarized state, at least a part of one of the metal elements A and B is substituted with a dopant element having a lower valence than the one of the metal elements A and B, and the composite oxide has a bandgap energy of 4 eV or more.Type: GrantFiled: December 9, 2020Date of Patent: January 17, 2023Assignees: DENSO CORPORATION, TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Yoshihiro Kozawa, Noriyuki Matsushita, Kazuhiko Kanoh, Yumi Tanaka, Tomoya Maruyama, Hiroshi Okamoto, Naoya Morioka, Katsuyoshi Saiki